NASDAQ: AMGNAmgen Inc Stock Forecast, Predictions & Price Target
Analyst price target for AMGN
Based on 16 analysts offering 12 month price targets for Amgen Inc.
Min Forecast
$185.00-19.81%
Avg Forecast
$261.13+13.18%
Max Forecast
$300.00+30.03%
Should I buy or sell AMGN stock?
Buy
Strong Buy
9 analysts 40.91%
Buy
1 analysts 4.55%
Hold
11 analysts 50.00%
Sell
0 analysts 0.00%
Strong Sell
1 analysts 4.55%
Forecast return on equity
Is AMGN forecast to generate an efficient return?
Company
103.14%
Industry
55.93%
Market
-1.26%
AMGN's Return on Equity is forecast to be high in 4 years (103.14%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is AMGN forecast to generate an efficient return on assets?
Company
16.91%
Industry
15.10%
Market
11.45%
AMGN is forecast to generate higher Return on Assets (16.91%) than the US Drug Manufacturers - General industry average (15.10%)
Forecast
AMGN earnings per share forecast
What is AMGN's earnings per share in the next 3 years based on estimates from 12 analysts?
Avg 1 year Forecast
$15.66+26.99%
Avg 2 year Forecast
$16.69+35.40%
Avg 3 year Forecast
$18.08+46.65%
AMGN's earnings are forecast to grow at a rate of 13.44% per year, which is not exceptional
Forecast
AMGN revenue forecast
What is AMGN's revenue in the next 3 years based on estimates from 10 analysts?
Avg 1 year Forecast
$25.4B+4.56%
Avg 2 year Forecast
$26.2B+7.77%
Avg 3 year Forecast
$27.0B+11.29%
AMGN's revenue is forecast to grow at a rate of 3.63% per year, which is not exceptional
Forecast
AMGN earnings growth forecast
How is AMGN forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
13.44%
Industry
20.04%
Market
14.77%
AMGN's earnings are forecast to grow slower (13.44% per year) than the US Drug Manufacturers - General industry average (20.04%)
Forecast
AMGN's earnings are forecast to grow slower (13.44% per year) than the US market average (14.77%)
Forecast
AMGN revenue growth forecast
How is AMGN forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
3.63%
Industry
6.42%
Market
5.69%
AMGN's revenues are forecast to grow slower (3.63% per year) than the US Drug Manufacturers - General industry average (6.42%)
Forecast
AMGN's revenues are forecast to grow slower (3.63% per year) than the US market average (5.69%)
Forecast
Amgen Stock Forecast FAQ
Is Amgen Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 22 Wall Street analysts covering (NASDAQ: AMGN) stock is to Buy AMGN stock.
Out of 22 analysts, 9 (40.91%) are recommending AMGN as a Strong Buy, 1 (4.55%) are recommending AMGN as a Buy, 11 (50.00%) are recommending AMGN as a Hold, 0 (0.00%) are recommending AMGN as a Sell, and 1 (4.55%) are recommending AMGN as a Strong Sell.
What is AMGN's Price Target?
According to 16 Wall Street analysts that have issued a 1 year AMGN price target, the average AMGN price target is $261.13, with the highest AMGN stock price forecast at $300.00 and the lowest AMGN stock price forecast at $185.00.
On average, Wall Street analysts predict that Amgen's share price could reach $261.13 by Oct 15, 2021. The average Amgen stock price prediction forecasts a potential upside of 13.18% from the current AMGN share price of $230.71.
What is AMGN's earnings growth forecast for 2020-2022?
(NASDAQ: AMGN) Amgen's forecast annual earnings growth rate of 13.44% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 20.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.77%.
Amgen's earnings in 2020 is $7,299,000,000.On average, 12 Wall Street analysts forecast AMGN's earnings for 2020 to be $9,210,483,650, with the lowest AMGN earnings forecast at $9,059,009,945, and the highest AMGN earnings forecast at $9,441,370,754. On average, 14 Wall Street analysts forecast AMGN's earnings for 2021 to be $9,820,378,553, with the lowest AMGN earnings forecast at $9,194,306,846, and the highest AMGN earnings forecast at $10,588,453,182.
In 2022, AMGN is forecast to generate $10,636,807,118 in earnings, with the lowest earnings forecast at $9,376,663,540 and the highest earnings forecast at $12,112,013,945.
What is AMGN's revenue growth forecast for 2020-2022?
(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 3.63% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.69%.
Amgen's revenue in 2020 is $24,301,000,000.On average, 10 Wall Street analysts forecast AMGN's revenue for 2020 to be $14,946,318,151,725, with the lowest AMGN revenue forecast at $14,762,068,477,905, and the highest AMGN revenue forecast at $15,133,840,834,073. On average, 10 Wall Street analysts forecast AMGN's revenue for 2021 to be $15,406,302,323,105, with the lowest AMGN revenue forecast at $15,042,074,239,829, and the highest AMGN revenue forecast at $15,978,093,501,118.
In 2022, AMGN is forecast to generate $15,909,615,621,400 in revenue, with the lowest revenue forecast at $15,516,201,643,423 and the highest revenue forecast at $16,312,688,621,669.
What is AMGN's Earnings Per Share (EPS) forecast for 2020-2022?
(NASDAQ: AMGN) Amgen's current Earnings Per Share (EPS) is $12.33. On average, analysts forecast that AMGN's EPS will be $15.66 for 2020, with the lowest EPS forecast at $15.40, and the highest EPS forecast at $16.05. On average, analysts forecast that AMGN's EPS will be $16.69 for 2021, with the lowest EPS forecast at $15.63, and the highest EPS forecast at $18.00. In 2022, AMGN's EPS is forecast to hit $18.08 (min: $15.94, max: $20.59).
What is AMGN's forecast return on equity (ROE) for 2020-2023?
(NASDAQ: AMGN) forecast ROE is 103.14%, which is considered strong.
What is AMGN's forecast return on assets (ROA) for 2020-2023?
(NASDAQ: AMGN) forecast ROA is 16.91%, which is higher than the forecast US Drug Manufacturers - General industry average of 15.10%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
